Eyal Fima

810 total citations
23 papers, 645 citations indexed

About

Eyal Fima is a scholar working on Immunology, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Eyal Fima has authored 23 papers receiving a total of 645 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 8 papers in Oncology and 6 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Eyal Fima's work include Immunotherapy and Immune Responses (7 papers), Immune Cell Function and Interaction (6 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). Eyal Fima is often cited by papers focused on Immunotherapy and Immune Responses (7 papers), Immune Cell Function and Interaction (6 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). Eyal Fima collaborates with scholars based in Israel, United States and Germany. Eyal Fima's co-authors include Ahuva Bar-Ilan, Oren Hershkovitz, Tatyana Dvorkin, Fuad Fares, Angel Porgador, Elena Voronov, Daniel Benharroch, Ron N. Apte, Shraga Segal and Olle Björkdahl and has published in prestigious journals such as Blood, The Journal of Immunology and PLoS ONE.

In The Last Decade

Eyal Fima

23 papers receiving 635 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eyal Fima Israel 13 336 248 139 94 72 23 645
Xue F. Huang United States 13 301 0.9× 291 1.2× 162 1.2× 35 0.4× 65 0.9× 21 621
Anke Theil Germany 8 261 0.8× 163 0.7× 150 1.1× 99 1.1× 154 2.1× 10 579
Fernando Díaz‐Espada Spain 12 263 0.8× 143 0.6× 80 0.6× 45 0.5× 38 0.5× 29 466
Anil K. Panigrahi United States 17 255 0.8× 446 1.8× 55 0.4× 39 0.4× 204 2.8× 29 849
Jeffery H. Carpenter United States 7 351 1.0× 316 1.3× 147 1.1× 22 0.2× 77 1.1× 8 662
Juha Ollila Finland 11 226 0.7× 416 1.7× 70 0.5× 214 2.3× 238 3.3× 15 800
Lone Frier Bovin Denmark 9 117 0.3× 171 0.7× 126 0.9× 23 0.2× 65 0.9× 11 376
Els Louagie Belgium 6 201 0.6× 230 0.9× 69 0.5× 20 0.2× 48 0.7× 8 494
Ivan H. Chan United States 10 393 1.2× 165 0.7× 362 2.6× 154 1.6× 78 1.1× 28 711
Luying Pan United States 9 167 0.5× 182 0.7× 49 0.4× 25 0.3× 86 1.2× 10 369

Countries citing papers authored by Eyal Fima

Since Specialization
Citations

This map shows the geographic impact of Eyal Fima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eyal Fima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eyal Fima more than expected).

Fields of papers citing papers by Eyal Fima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eyal Fima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eyal Fima. The network helps show where Eyal Fima may publish in the future.

Co-authorship network of co-authors of Eyal Fima

This figure shows the co-authorship network connecting the top 25 collaborators of Eyal Fima. A scholar is included among the top collaborators of Eyal Fima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eyal Fima. Eyal Fima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Strasburger, Christian J., Peter Vaňuga, Juraj Payer, et al.. (2016). MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults. European Journal of Endocrinology. 176(3). 283–294. 38 indexed citations
2.
Hershkovitz, Oren, Ahuva Bar-Ilan, Rachel Guy, et al.. (2015). In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone. Molecular Pharmaceutics. 13(2). 631–639. 35 indexed citations
3.
Zadik, Zvi, Ron G. Rosenfeld, Nataliya Zelinska, et al.. (2014). Top Line Results of Once-Weekly, CTP-Modified Human GH (MOD-4023): Phase 2 Dose Finding Study in Children with GH Deficiency. 82. 4 indexed citations
4.
Fares, Fuad, et al.. (2013). Patents on Enhancing the Potency and Longevity of Highly Valuable Protein Hormones. Recent Patents on Endocrine Metabolic & Immune Drug Discovery. 7(2). 148–154. 3 indexed citations
5.
6.
Popović–Bugarin, Vesna, Miklós Góth, Peter Vaňuga, et al.. (2012). Once-weekly, CTP-modified hGH (MOD-4023) is effective in growth hormone deficient adults: a phase II, dose and frequency finding study. 15th International & 14th European Congress of Endocrinology. 29. 5 indexed citations
7.
8.
Góth, Miklós, Peter Vaňuga, Juraj Payer, et al.. (2012). P03-37 Once-weekly, CTP-modified hGH (MOD-4023) is effective in growth hormone deficient adults: A phase II, dose and frequency finding study. Growth Hormone & IGF Research. 22. S84–S85. 1 indexed citations
9.
10.
11.
Arnon, Tal I., Gal Markel, Ahuva Bar-Ilan, et al.. (2008). Harnessing Soluble NK Cell Killer Receptors for the Generation of Novel Cancer Immune Therapy. PLoS ONE. 3(5). e2150–e2150. 27 indexed citations
12.
Zilka, Alon, Guy Landau, Oren Hershkovitz, et al.. (2005). Characterization of the Heparin/Heparan Sulfate Binding Site of the Natural Cytotoxicity Receptor NKp46. Biochemistry. 44(44). 14477–14485. 39 indexed citations
13.
Qimron, Udi, Ahuva Bar-Ilan, Oren Hershkovitz, et al.. (2004). Membrane-Associated Heparan Sulfate Proteoglycans Are Involved in the Recognition of Cellular Targets by NKp30 and NKp46. The Journal of Immunology. 173(4). 2392–2401. 119 indexed citations
14.
Song, Xiaoping, Elena Voronov, Tatyana Dvorkin, et al.. (2003). Differential Effects of IL-1α and IL-1β on Tumorigenicity Patterns and Invasiveness. The Journal of Immunology. 171(12). 6448–6456. 136 indexed citations
15.
Fima, Eyal, et al.. (2003). PKCη associates with cyclin E/Cdk2 complex in serum-starved MCF-7 and NIH-3T3 cells. Experimental Cell Research. 286(1). 22–29. 19 indexed citations
16.
Fima, Eyal, et al.. (2001). PKCη enhances cell cycle progression, the expression of G1 cyclins and p21 in MCF-7 cells. Oncogene. 20(46). 6794–6804. 47 indexed citations
17.
Fima, Eyal, et al.. (1999). Expression of PKCeta in NIH-3T3 cells promotes production of the pro-inflammatory cytokine interleukin-6.. PubMed. 10(4). 491–500. 13 indexed citations
18.
Douvdevani, Amos, Margot Zöller, Tatyana Dvorkin, et al.. (1994). Involvement of immune responses in the eradication of IL-1 alpha gene-transduced tumour cells: mechanisms of tumour rejection and immunotherapeutical implications.. PubMed. 40(1-2). 1–18. 8 indexed citations
19.
Apte, Ron N., Amos Douvdevani, Margot Zöller, et al.. (1993). Cytokine-induced tumor immunogenicity: endogenous interleukin-1α expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunology Letters. 39(1). 45–52. 34 indexed citations
20.
Apte, Ron N., Amos Douvdevani, Mahmoud Huleihel, et al.. (1992). IL-1 and pro-inflammatory cytokines produced by primary and transformed fibroblasts abrogate the tumorigenic potential of fibrosarcomas.. PubMed. 38(3-4). 240–57. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xue F. Huang Breakdown of academic impact, for papers by Anke Theil Breakdown of academic impact, for papers by Fernando Díaz‐Espada Breakdown of academic impact, for papers by Anil K. Panigrahi Breakdown of academic impact, for papers by Jeffery H. Carpenter Breakdown of academic impact, for papers by Juha Ollila Breakdown of academic impact, for papers by Lone Frier Bovin Breakdown of academic impact, for papers by Els Louagie Breakdown of academic impact, for papers by Ivan H. Chan Breakdown of academic impact, for papers by Luying Pan
Rankless by CCL
2026